Break Down Barriers to Providing Buprenorphine for OUD
April 2025
You play a crucial role in ensuring patients have access to buprenorphine products (Suboxone, etc) for opioid use disorder (OUD).
We know buprenorphine is a first-line treatment for OUD.
But many patients who want or need treatment still can’t get it...despite changes to help increase access. For example, DEA-registered clinicians no longer need an “X” waiver to prescribe buprenorphine.
Get concise advice on drug therapy, plus unlimited access to CE
Hospital Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote